Considerations for Human <scp>ADME</scp> Strategy and Design Paradigm Shift(s) – An Industry White Paper-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White Paper

Published:2022-09-02 Issue:4 Volume:113 Page:775-781
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Young Graeme C.¹^ORCID,Spracklin Douglas K.²,James Alexander D.³,Hvenegaard Mette G.⁴,Scarfe Graeme⁵,Wagner David S.⁶,Georgi Katrin⁷,Schieferstein Hanno⁷,Bjornsdottir Inga⁸,van Groen Bianca⁹^ORCID,Romeo Andrea A.⁹^ORCID,Cassidy Kenneth C.¹⁰,Da‐violante Georges¹¹,Bister Bojan¹²,Blech Stefan¹²,Lyer Ramaswamy¹³,Schulz Simone I.¹⁴,Cuyckens Filip¹⁵,Moliner Patricia¹⁶

Affiliation:

1. GlaxoSmithKline Research & Development Ltd. David Jack Centre Ware UK

2. Pfizer Inc. Groton Connecticut USA

3. Novartis Basel Switzerland

4. H.Lundbeck A/S Copenhagen Denmark

5. AstraZeneca, Cambridge Biomedical Campus Cambridge UK

6. AbbVie North Chicago Illinois USA

7. The Healthcare Business of Merck KGaA Darmstadt Germany

8. Novo Nordisk Maaloev Denmark

9. Roche Pharma Research and Early Development Basel Switzerland

10. Eli Lilly and Company Indianapolis Indiana USA

11. Technologie Servier Orleans France

12. Boehringer‐Ingelheim Pharma GmbH & Co. KG Biberach Germany

13. Bristol‐Myers Squibb Monroe New Jersey USA

14. Bayer AG Wuppertal Germany

15. Janssen R&D Beerse Belgium

16. Sanofi Montpellier, Occitanie France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2691

Reference41 articles.

1. Human radiolabeled mass balance studies: objectives, utilities and limitations

2. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?

3. Radiolabeled mass‐balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary;White R.E.;Xenobiotica

4. AMS in drug development: Exploring the current utility of AMS and future opportunities for absolute bioavailability and ADME investigations

5. Mini‐Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals;Regulatory Toxicology and Pharmacology;2024-09

2. Metabolite analysis of 14C-labeled chloromethylisothiazolinone/methylisothiazolinone for toxicological consideration of inhaled isothiazolinone biocides in lungs;Chemosphere;2024-08

3. Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining¹⁹F-NMR (Nuclear Magnetic Resonance),¹H-NMR, and High-Resolution Mass Spectrometric Analyses;Drug Metabolism and Disposition;2024-05-20

4. Small molecule drug metabolite synthesis and identification: why, when and how?;Drug Discovery Today;2024-05

5. Gut Microbiome Integration in Drug Discovery and Development of Small Molecules;Drug Metabolism and Disposition;2024-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3